STOCK TITAN

Atea Pharmaceuticals, Inc. - AVIR STOCK NEWS

Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to discovering, developing, and commercializing oral antiviral therapies aimed at treating severe viral diseases. Founded in 2012, Atea focuses on addressing unmet medical needs, particularly in serious viral infections caused by single-stranded RNA viruses.

The company's leading product candidate is AT-527 (bemnifosbuvir), an antiviral agent developed for treating COVID-19, caused by the SARS-CoV-2 virus. Currently, AT-527 is undergoing Phase 3 clinical trials. Additionally, the combination of bemnifosbuvir and ruzasvir, an oral NS5A inhibitor, is being developed for treating Hepatitis C Virus (HCV) and has shown promising results in Phase 2 trials. This combination therapy aims to provide a highly potent pan-genotypic antiviral treatment with a short treatment duration and fewer contraindications, particularly beneficial for HCV patients.

Beyond COVID-19 and HCV, Atea is also advancing other antiviral therapies in its pipeline, including AT-787 for Hepatitis C (under Phase 2 clinical trial), AT-752 for Dengue (under Phase 2 trial), and other candidates like AT-889 and AT-934 for Respiratory Syncytial Virus (currently under clinical trials).

Recent achievements include positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV, showing a 97% sustained virologic response rate at 12 weeks post-treatment. Furthermore, Atea has completed enrollment for the Phase 3 SUNRISE-3 trial for treating high-risk COVID-19 patients, with results expected in the second half of 2024.

Financially, Atea reported a solid cash position of $578.1 million as of December 31, 2023, enabling them to continue advancing their clinical programs. Collaborations and strategic partnerships play a crucial role in Atea’s progress, helping to broaden its scope and enhance its therapeutic offerings.

Investors and stakeholders can stay informed about Atea’s developments through their regular updates, financial reports, and participation in industry conferences. For more information, visit their official website at www.ateapharma.com.

Rhea-AI Summary

Atea Pharmaceuticals announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. ET. CEO Jean-Pierre Sommadossi and the management team will engage in a fireside chat. A live webcast will be accessible on Atea's website, with a replay available for 90 days post-event. Atea focuses on developing oral therapies for severe viral diseases, leveraging its proprietary nucleotide prodrug platform to target viruses like SARS-CoV-2 and HCV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
-
Rhea-AI Summary

Atea Pharmaceuticals (AVIR) announced promising data for its dengue virus treatment candidate, AT-752, published in Antimicrobial Agents and Chemotherapy. The research shows AT-752 has potent in vitro and in vivo activity against multiple dengue virus serotypes, reducing viremia and improving survival rates in animal models. The Phase 1a clinical trial demonstrated good tolerance with no serious adverse events at doses up to 1500 mg. Dengue fever is a significant global health issue, with 400 million infections annually, highlighting the urgency for effective antiviral treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary

Atea Pharmaceuticals (AVIR) announced promising interim Phase 2 results for AT-527, a COVID-19 treatment, showing rapid viral load decrease in hospitalized patients. The active metabolite achieved target antiviral levels in lung fluid, critical for effective treatment. Collaboration with Roche continues, facilitating multiple ongoing clinical studies. Financially, Q2 2021 collaboration revenue reached $60.4 million, with a net income of $1.5 million, significantly improving from a loss in the previous year. Cash reserves stand at $816.5 million, reflecting strong financial backing for ongoing development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.06%
Tags
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced a live conference call and audio webcast on August 12, 2021, at 4:30 p.m. ET to discuss its second-quarter financial results and provide a clinical update. The call can be accessed via phone or through the company's website. Atea focuses on developing oral therapeutics for severe viral infections, utilizing a proprietary nucleotide prodrug platform for treating viruses such as SARS-CoV-2, HCV, and RSV. For more information, visit Atea Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
conferences earnings
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will participate in a fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 p.m. ET. A live webcast will be available on Atea's website, with a replay accessible for 90 days post-event.

Atea is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for severe viral infections, including COVID-19, using its proprietary nucleotide prodrug platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
conferences
-
Rhea-AI Summary

Atea Pharmaceuticals announced promising interim results from its global Phase 2 study of AT-527, an oral antiviral for COVID-19, showing significant viral load reductions in hospitalized patients. In 70 high-risk patients, those receiving AT-527 exhibited an 80% greater mean reduction in viral load by Day 2 compared to placebo. Clearance of SARS-CoV-2 was observed in 47% of patients by Day 14. AT-527 demonstrated a favorable safety profile with no drug-related serious adverse events. Ongoing trials include Phase 2 MOONSONG and Phase 3 MORNINGSKY, with more results expected in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
clinical trial covid-19
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) has achieved a significant milestone by securing a $50 million payment under its license agreement with Roche for the development of AT-527, an oral antiviral for COVID-19. This payment reflects the ongoing collaboration and progress in clinical trials, including the global Phase 3 MORNINGSKY trial. Atea retains commercialization rights in the U.S., while Roche holds them outside the U.S. AT-527 is designed to minimize viral replication and could be used in both pre- and post-exposure prophylactic settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Summary

Atea Pharmaceuticals has appointed Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Previously at Gilead Sciences, Dr. Avila brings significant experience in medical affairs focusing on COVID-19 and other viral diseases. CEO Jean-Pierre Sommadossi expressed confidence in Dr. Avila’s expertise to enhance Atea’s capabilities, particularly in advancing its antiviral pipeline, including AT-527 for COVID-19. Atea aims to develop innovative oral therapeutics for severe viral infections, leveraging its proprietary nucleotide prodrug platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
management
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET. The presentation will include insights into Atea's focus on developing oral therapeutics for severe viral infections, particularly for ssRNA viruses like SARS-CoV-2, the virus causing COVID-19. A live webcast of the event can be accessed here. A replay will be available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
conferences
Rhea-AI Summary

Atea Pharmaceuticals has appointed Jerome Adams, M.D., M.P.H., former U.S. Surgeon General, to its Board of Directors. Dr. Adams brings extensive experience in clinical practice, public health, and leadership roles, particularly during the COVID-19 pandemic. His expertise will support Atea's ongoing global Phase 3 clinical trial for AT-527, an oral antiviral aimed at treating COVID-19. Atea focuses on developing innovative therapies for severe viral infections, leveraging its proprietary nucleotide prodrug platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
management

FAQ

What is the current stock price of Atea Pharmaceuticals (AVIR)?

The current stock price of Atea Pharmaceuticals (AVIR) is $3.19 as of December 20, 2024.

What is the market cap of Atea Pharmaceuticals (AVIR)?

The market cap of Atea Pharmaceuticals (AVIR) is approximately 267.7M.

What is Atea Pharmaceuticals, Inc.?

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral antiviral therapies for severe viral diseases.

What are the main products developed by Atea Pharmaceuticals?

Atea's lead product candidate is AT-527 (bemnifosbuvir) for COVID-19, and they are also developing a combination of bemnifosbuvir and ruzasvir for Hepatitis C Virus (HCV).

What is the status of the AT-527 (bemnifosbuvir) clinical trials?

AT-527 is currently in Phase 3 clinical trials for treating COVID-19, with significant progress reported in patient enrollment and trial milestones.

What recent achievements has Atea Pharmaceuticals made?

Recent achievements include the completion of Phase 3 SUNRISE-3 trial enrollment for COVID-19 and positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV.

Where is Atea Pharmaceuticals headquartered?

Atea Pharmaceuticals is headquartered in Boston, Massachusetts.

How does Atea Pharmaceuticals plan to address unmet medical needs?

Atea aims to address unmet medical needs by developing potent, short-duration antiviral therapies with fewer contraindications, particularly for serious viral infections like HCV and COVID-19.

What is the financial condition of Atea Pharmaceuticals?

As of December 31, 2023, Atea reported a strong cash position of $578.1 million, supporting the advancement of their clinical programs and operations.

How can I get more information about Atea Pharmaceuticals?

For more information, visit Atea Pharmaceuticals' official website at www.ateapharma.com.

What are the expected upcoming events for Atea Pharmaceuticals?

Upcoming events include the anticipated release of full results from the ongoing Phase 2 HCV study and the Phase 3 SUNRISE-3 COVID-19 trial in the second half of 2024.

Who should be interested in Atea Pharmaceuticals’ updates?

Investors, stakeholders, healthcare professionals, and patients interested in advancements in antiviral therapies for serious viral infections should follow Atea Pharmaceuticals’ updates.

Atea Pharmaceuticals, Inc.

Nasdaq:AVIR

AVIR Rankings

AVIR Stock Data

267.75M
76.32M
9.67%
71%
3.12%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON